JP7115758B2 - Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ - Google Patents

Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ Download PDF

Info

Publication number
JP7115758B2
JP7115758B2 JP2019546903A JP2019546903A JP7115758B2 JP 7115758 B2 JP7115758 B2 JP 7115758B2 JP 2019546903 A JP2019546903 A JP 2019546903A JP 2019546903 A JP2019546903 A JP 2019546903A JP 7115758 B2 JP7115758 B2 JP 7115758B2
Authority
JP
Japan
Prior art keywords
cd16a
amino acid
antigen
cells
bcma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019546903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510659A (ja
JP2020510659A5 (enExample
Inventor
ロス トルステン
フチェク イビツァ
エルヴァンゲル クリスティーナ
ヴァイヒェル ミカエル
ロイシュ ウーベ
ナックムス シュテファン
ライコビッチ エリッヒ
トレデル マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of JP2020510659A publication Critical patent/JP2020510659A/ja
Publication of JP2020510659A5 publication Critical patent/JP2020510659A5/ja
Application granted granted Critical
Publication of JP7115758B2 publication Critical patent/JP7115758B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019546903A 2017-02-28 2018-02-28 Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ Active JP7115758B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17158566 2017-02-28
EP17158566.4 2017-02-28
EP17174407 2017-06-02
EP17174407.1 2017-06-02
PCT/EP2018/054989 WO2018158349A1 (en) 2017-02-28 2018-02-28 Tandem diabody for cd16a-directed nk-cell engagement

Publications (3)

Publication Number Publication Date
JP2020510659A JP2020510659A (ja) 2020-04-09
JP2020510659A5 JP2020510659A5 (enExample) 2021-04-01
JP7115758B2 true JP7115758B2 (ja) 2022-08-09

Family

ID=61569251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019546903A Active JP7115758B2 (ja) 2017-02-28 2018-02-28 Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ

Country Status (8)

Country Link
US (2) US11180558B2 (enExample)
EP (1) EP3589655B1 (enExample)
JP (1) JP7115758B2 (enExample)
CN (1) CN110382539B (enExample)
AU (1) AU2018228719B2 (enExample)
CA (1) CA3051062C (enExample)
DK (1) DK3589655T3 (enExample)
WO (1) WO2018158349A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12020551664B1 (en) * 2018-04-13 2023-05-19 Affimed Gmbh Nk cell engaging antibody fusion constructs
JP2023545099A (ja) * 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
EP4240768A2 (en) * 2020-11-06 2023-09-13 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
EP4286410A4 (en) * 2021-01-27 2025-03-12 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibodies against CD16A and use thereof
WO2023274183A1 (zh) * 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
IL312515A (en) * 2021-11-03 2024-07-01 Affimed Gmbh Bispecific cd16a binders
EP4426439A1 (en) * 2021-11-03 2024-09-11 Affimed GmbH Bispecific cd16a binders
CN114262382B (zh) * 2021-12-20 2023-09-19 上海恩凯细胞技术有限公司 双特异性抗体及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN115960234B (zh) * 2022-10-27 2023-12-29 合肥天港免疫药物有限公司 抗cd16a的抗体及其应用
AU2023411854A1 (en) 2022-12-19 2025-07-10 Harbour Biomed (Shanghai) Co., Ltd. “kappa/lambda” fab-fab series-connection multi-specific binding protein, preparation thereof, and use thereof
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513805A (ja) 1998-05-05 2002-05-14 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 多価抗体構築物
JP2008541714A (ja) 2005-05-26 2008-11-27 アフィメート テラポイティクス アーゲー 抗ｃｄ１６結合分子
JP2014527515A (ja) 2011-07-22 2014-10-16 アフィメート テラポイティクス アーゲー 多価抗原結合Ｆｖ分子
WO2016177846A1 (en) 2015-05-04 2016-11-10 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
JP2016536322A (ja) 2013-08-07 2016-11-24 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ ＥＧＦＲｖＩＩＩに対して特異的な抗体結合部位

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
DE60127143T2 (de) * 2001-11-14 2007-11-15 Affimed Therapeutics Ag Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
EP3424951A1 (en) * 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
NZ594985A (en) 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
PT2361936T (pt) * 2010-02-25 2016-07-15 Affimed Gmbh Molécula que se liga a antigénio e utilizações desta
US20110206672A1 (en) * 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
MX351069B (es) 2011-05-27 2017-09-29 Glaxo Group Ltd Proteinas de union abcma (cd269/tnfrsf17).
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AU2013340799B2 (en) 2012-11-01 2018-08-09 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513805A (ja) 1998-05-05 2002-05-14 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 多価抗体構築物
JP2008541714A (ja) 2005-05-26 2008-11-27 アフィメート テラポイティクス アーゲー 抗ｃｄ１６結合分子
JP2014527515A (ja) 2011-07-22 2014-10-16 アフィメート テラポイティクス アーゲー 多価抗原結合Ｆｖ分子
JP2016536322A (ja) 2013-08-07 2016-11-24 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ ＥＧＦＲｖＩＩＩに対して特異的な抗体結合部位
WO2016177846A1 (en) 2015-05-04 2016-11-10 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Affimed and MD Anderson Announce Clinical Immuno-Oncology Development Collaboration，THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Press Release，2017年01月04日，https://www.affimed.com/wp-content/uploads/20170104_afmd_mdacc_collaboration_final-rev.pdf
Reusch,Uwe, et al.，A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells，mAbs，2014年，Vol. 6, No. 3，pp. 727-738，https://doi.org/10.4161/mabs.28591
Rothe,Achim, et al.，A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma，Blood，2015年，Vol. 125, No. 26，pp. 4024-4031，https://doi.org/10.1182/blood-2014-12-614636

Also Published As

Publication number Publication date
EP3589655B1 (en) 2022-10-26
JP2020510659A (ja) 2020-04-09
CN110382539B (zh) 2023-08-08
US20220041717A1 (en) 2022-02-10
DK3589655T3 (da) 2022-11-28
US11180558B2 (en) 2021-11-23
CN110382539A (zh) 2019-10-25
CA3051062A1 (en) 2018-09-07
CA3051062C (en) 2023-09-26
AU2018228719B2 (en) 2023-03-30
US12264198B2 (en) 2025-04-01
EP3589655A1 (en) 2020-01-08
US20190345249A1 (en) 2019-11-14
WO2018158349A1 (en) 2018-09-07
AU2018228719A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
JP7115758B2 (ja) Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
US20240294647A1 (en) Uses of nk cell engaging antibody fusion constructs for treatments
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
KR102838691B1 (ko) 이중특이적 체크포인트 억제제 항체
US20220251202A1 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
JP2019533444A (ja) ＩＬ−１５／ＩＬ−１５ＲアルファＦｃ融合タンパク質およびＰＤ−１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
CN110325209A (zh) 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
US20250051444A1 (en) Multi-specific t cell engagers comprising lrrc15 antigen-binding domain
JP2024521701A (ja) 抗ｃｄ１３７抗体及びその使用方法
US20240209113A1 (en) Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
RU2774711C2 (ru) Слитые конструкции антител для вовлечения nk-клеток
CA3210650A1 (en) Bispecific antibodies enhancing cell mediated immune responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220721

R150 Certificate of patent or registration of utility model

Ref document number: 7115758

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250